Literature DB >> 3129989

In vitro susceptibilities of common pediatric pathogens to LY163892.

S Shelton1, J D Nelson.   

Abstract

LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and amoxicillin-clavulanic acid. It has greater stability than cefaclor and greater activity against beta-lactamase-producing Haemophilus influenzae and Escherichia coli. LY163892 is less active than amoxicillin against streptococci and less active than amoxicillin-clavulanic acid against Branhamella catarrhalis but comparable against other pathogens.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3129989      PMCID： PMC172150          DOI： 10.1128/AAC.32.2.268

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Pharmacokinetics of loracarbef in pediatric patients.

Authors:  M C Nahata; K I Koranyi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

2.  Loracarbef concentrations in middle ear fluid.

Authors:  H Kusmiesz; S Shelton; O Brown; S Manning; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  Influence of storage and susceptibility test conditions on stability and activity of LY163892 and four other cephalosporins.

Authors:  J H Jorgensen; J S Redding; L A Maher
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

Review 4.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media.

Authors:  V N Gan; H Kusmiesz; S Shelton; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

6.  Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.

Authors:  O Müller; Z Spirer; K Wettich
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

7.  Pharmacokinetics of loracarbef and interaction with acetylcysteine.

Authors:  S Roller; H Lode; I Stelzer; K M Deppermann; M Boeckh; P Koeppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

8.  Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.

Authors:  O Müller; K Wettich
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

9.  Pharmacokinetics of LY163892 in infants and children.

Authors:  J D Nelson; S Shelton; H Kusmiesz
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 10.  The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.

Authors:  Jonathan Turner; Alyssa Muraoka; Michael Bedenbaugh; Blaine Childress; Lauren Pernot; Mark Wiencek; Yuri K Peterson
Journal:  Front Microbiol       Date:  2022-03-24       Impact factor: 5.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.